Hims Investors Have Opportunity to Lead Securities Fraud Lawsuit

New York – Rosen Law Firm, a global investor rights law firm, has notified purchasers of Hims & Hers Health, Inc. (NYSE: HIMS) securities of the important November 2, 2026 lead plaintiff deadline in a securities fraud class action. Investors who bought Hims securities during the Class Period may be entitled to compensation without out-of-pocket costs through a contingency fee arrangement.

The lawsuit alleges that defendants made materially false and misleading statements and/or failed to disclose crucial information about Hims & Hers Health's business operations. Specifically, the complaint claims Hims shared consumer health information with third-party advertising platforms and charged consumers for prescriptions almost immediately after intake forms were submitted, contrary to assurances of consultation for appropriate treatment.

According to the allegations, these practices subjected Hims to regulatory scrutiny and potential fees and penalties. The firm contends that when the true details of these operations entered the market, investors suffered damages as a result of the materially misleading statements and lack of reasonable basis in the company's positive public statements.

Rosen Law Firm encourages investors who purchased Hims securities between August 4, 2025, and July 29, 2026, to contact them for information on how to participate. The deadline to move the Court to serve as lead plaintiff is November 2, 2026. The firm emphasizes selecting qualified counsel with a track record in securities class actions.

The law firm has significant experience in securities class actions and shareholder derivative litigation, having recovered billions of dollars for investors in numerous cases.